Background: Trastuzumab has significantly improved survival outcomes for women with HER2 positive early breast cancer. Trastuzumab was established as a costeffective adjuvant treatment in 2006. We present an updated cost-effectiveness analysis from the UK perspective which explores assumptions...

There is a need to understand the practicality, validity and reliability of using utility measures with children and adolescents. We designed a pilot study in order to help guide the selection of an appropriate health-related quality of life (HRQoL) questionnaire for adolescents to be used in...

Background: Trastuzumab has significantly improved survival outcomes for women with Human Epidermal growth factor Receptor 2 (HER2)-positive early breast cancer. Trastuzumab was established as a cost-effective adjuvant treatment in 2006. We present an updated cost-effectiveness analysis from the...